The DOI matches its Crossref record; 213 of the 214 references it cites were found in a registry or an index.
Hepatic glucose metabolism in the steatotic liver
Abstract
The liver is central in regulating glucose homeostasis, being the major contributor to endogenous glucose production and the greatest reserve of glucose as glycogen. It is both a target and regulator of the action of glucoregulatory hormones. Hepatic metabolic functions are altered in and contribute to the highly prevalent steatotic liver disease (SLD), including metabolic dysfunction-associated SLD (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). In this Review, we describe the dysregulation of hepatic glucose metabolism in MASLD and MASH and associated metabolic comorbidities, and how advances in techniques and models for the assessment of hepatic glucose fluxes in vivo have led to the identification of the mechanisms related to the alterations in glucose metabolism in MASLD and comorbidities. These fluxes can ultimately increase hepatic glucose production concomitantly with fat accumulation and alterations in the secretion and action of glucoregulatory hormones. No pharmacological treatment has yet been approved for MASLD or MASH, but some antihyperglycaemic drugs approved for treating type 2 diabetes have shown positive effects on hepatic glucose metabolism and hepatosteatosis. A deep understanding of how MASLD affects glucose metabolic fluxes and glucoregulatory hormones might assist in the early identification of at-risk individuals and the use or development of targeted therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the liver, glucose metabolism is mainly regulated by, among other hormones, insulin and glucagon, as well as by substrate availability (Scoditti et al, 2024).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Scoditti et al, 2024
In the citing paper
“Thus, the study indicates that mitochondrial function initially increases in a compensatory manner, but after eventually reaches a limit, beyond which mitochondrial dysfunction seems to contribute to the progression to MASH and hepatic fibrosis [14,66].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [14]
In the citing paper
“This ChREBP-FGF21 pathway requires PPARα and serves as a protective feedback loop against carbohydrate overconsumption and metabolic disease [14].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [14]
In the citing paper
“The increase in DNL, often observed in metabolic diseases, is also due to the overactivation of the transcription factors that stimulate DNL, e.g. sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate-responsive-element-binding-protein (ChREBP), which can promote the development of MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [7]
In the citing paper
“Ceramides are recognised as key mediators of hepatic IR.7,104,116”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [7]
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“It is of note that patients with SLD, even with normal weight or overweight, have increased VAT compared with healthy individuals 54 , impaired lipolysis and elevated plasma FFA 46,86,87 independently of obesity 38,54 .”
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“…of the main results in MASLD obtained following treatment with a single GLP1RA, including short-acting exenatide 174,181–185 , liraglutide 173,186,187 and lixisenatide 188 , and long-acting GLP1RA semaglutide 189 and dulaglutide 190 ; DPP4 inhibitors, such as sitagliptin, have no effects on…”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“…EGP as well as Hep-IR in 434 Pima Native Americans without T2D 52 , a population at high risk of T2D and SLD. High fasting glucose, insulin, EGP and Hep-IR were also reported in individuals with MASH by Belfort and colleagues 53 and Saponaro and colleagues 54 ( n = 55 and n = 32, respectively).”
Self-citationMolecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“contributing to the progression to MASH 124,125 .”
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 1×
“These effects are thought to occur mainly through indirect pancreatic hormones and/or neural-mediated mechanisms because controversy exists regarding the hepatic, muscle and adipose expression of GLP1 receptors 176–178 .”
Research works printed but not linked: 1
- Wolfe, R. R. & Chinkes, D. L. Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis (Wiley, 2004).
Cited by
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Singh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“7 Sugars can activate ChREBP, while insulin, secreted in response to hyperglycaemia, activates SREBP1c (Fig.”
Self-citationEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Metadata
- Authors
- Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A.
- Affiliations
- National Research Council (IT)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Gastaldelli, Amalia
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2024-02-02
- Volume
- 21
- Issue
- 5
- Pages
- 319-334
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W4391466814
- Cited by
- 134
- References
- 214
- Citations by year
- 2026: 56 · 2025: 59 · 2024: 19
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hepatic glucose metabolism, steatotic liver disease, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, hepatic glucose production, glucoregulatory hormones, hepatic lipid accumulation, obesity, type 2 diabetes, antidiabetic drugs, glucose homeostasis
- MeSH terms
- Fatty Liver, Glucose, Humans, Liver
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatic glucose metabolism in the steatotic liver. https://app.cochat.ai/papers/10.1038/s41575-023-00888-8
- The paper
- Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024). Hepatic glucose metabolism in the steatotic liver. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-023-00888-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.